Molecular analysis using SalvGlandDx improves risk of malignancy estimation and diagnosis of salivary gland cytopathology: An exploratory multicenter study
Sandra N. Freiberger(University of Zurich), Niels J. Rupp(University Hospital of Zurich), Esther Hauben(Universitair Ziekenhuis Leuven), Vincent Vander Poorten(KU Leuven), Demi van Egmond(Leiden University Medical Center), Kristian Ikenberg(University Hospital of Zurich), Isabelle Vanden Bempt(KU Leuven), Simon A. Mueller(University Hospital Zurich), Jeroen N. van Rossem(Leiden University Medical Center), Sofie Claerhout(KU Leuven), Paul M. Clément(Universitair Ziekenhuis Leuven), Daniëlle Cohen(Royal Hallamshire Hospital), Tom van Wezel(Leiden University Medical Center)
Cited by 15
Related Papers
Lomustine and Bevacizumab in Progressive Glioblastoma
|New England Journal of Medicine|2017|994
Randomized Phase II Trial of Erlotinib Versus Temozolomide or Carmustine in Recurrent Glioblastoma: EORTC Brain Tumor Group Study 26034
|Journal of Clinical Oncology|2009|573
Temozolomide chemotherapy versus radiotherapy in high-risk low-grade glioma (EORTC 22033-26033): a randomised, open-label, phase 3 intergroup study
|The Lancet Oncology|2016|504